Clinical and Laboratory Factors for the Progression of Severe Dengue Among Hospitalized Patients During an Upsurge
NCT ID: NCT06697041
Last Updated: 2025-04-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
324 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-01-01
Study Completion Date
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis (if any): Not applicable Objectives: To identify factors for progression to severe Dengue in hospitalized patients.
Methods: Prospective Observational study
Methods: Prospective Observational study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Responses to Dengue and Sepsis
NCT07040202
Dengue
Sepsis
RECRUITING
Severe Dengue in Critical Care at Villavicencio, Colombia.
NCT05938647
Severe Dengue
RECRUITING
Prediction of Disease Severity in Young Children Presenting With Acute Febrile Illness in Resource-limited Settings
NCT04285021
Sepsis
COMPLETED
Community Acquired Sepsis Cohort
NCT03280992
Severe Septic Syndrome
Septic Shock
TERMINATED
Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism
NCT02361970
Sepsis
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Global perspective:
Mosquito-borne dengue is a global public health issue in the tropics and subtropics. Dengue is endemic in over 100 countries, according to WHO. Around 40% of the world's population-3.6 billion-lives in dengue-endemic areas. Dengue infects 400 million people, sickens 100 million, and kills 21,000 each year. In studies of acute febrile illness in US visitors returning from South-central and Southeast Asia, South America, Mexico, and the Caribbean, dengue is the main cause due to increased international travel and the popularity of dengue-endemic destinations. Thus, dengue-related US hospitalizations are rising. Prevention methods, such as early detection and prompt clinical therapy, can lower case fatality rates from 10% to \<1%.
National perspective:
Dengue has been hyperendemic in Bangladesh since 2000. The current dengue spike is exceptional in its seasonality and an early fast increase compared to past years, which began in late June. According to WHO, this year's case fatality rate is 0.47%, higher than usual. However, Bangladeshi clinical spectrum, serotype predominance, novel and modified serotypes (DEVN-5), and immunological responses need more research. However, future dengue prevention and treatment techniques require serotype-specific clinical and laboratory indicators and immune reactivity in distinct spectrums.
This research is conducted in hospitals to identify the burden of severe dengue and its link to dengue fever in our country. Dengue fever is now managed supportively without antiviral medication. The cause of severe and potentially deadly dengue is unknown. Prior DENV exposure, co-morbidity, and genetic predisposition may increase the risk of severe dengue sickness. The study results will help us understand and solve the problem. The aim is to assess the clinical and laboratory parameters related to severe Dengue and the transition from non-severe to severe Dengue in hospitalized Bangladeshis.
Primary objectives: To identify factors for progression to severe Dengue in hospitalized patients.
Secondary objectives:
1. To determine the circulating dengue serotype (DENV-1, DENV-2, DENV-3, DNEV-4, and others) about different spectrums of dengue fever in Bangladesh.
2. To determine primary and secondary immune responses (IgG and IgM) following dengue infection \[by examining IgG to IgM ratio (ELISA) with analyzing of DENV NS1 IgG subclass types (ELISA)\] and the association of immune responses to the different spectrum of dengue fever in Bangladesh.
3. To characterize specific laboratory biomarkers (hematocrit level, white blood cell count, platelet count, coagulation profile, serum albumin level, liver enzymes, LDH) and immunological parameters (NS1, IgM, and IgG) associated with severe Dengue cases.
4. Verbal autopsy and retrospective analyses of death cases from the respective hospital.
5. To explore physicians' barriers and challenges in treating Dengue and identify and develop the best treatment approaches through formative research.
Study design: Observational Cohort study Study sites: Four sites/hospitals: Dhaka North City Corporation Hospital (DNCCH), Mugda Medical College and Hospital (MuMCH), Dhaka Medical College Hospital (DMCH), and Dhaka Hospital of icddr,b.
Study population: \>1 year Study period: The study lasts from 1 January 2024 to 31 June 2024. Total enrolment will be for 6 months or until the estimated patient enrolment is fulfilled.
Study Activities:
Screening: The study nurse and health worker will identify eligible patients during hospital admission. After meeting enrolment requirements, the caregiver or attendance will be asked for informed written consent. After consenting, the patient will be enrolled. Patients will give a full history, and the study nurse will record it in CRF. Socio-demographic, household, co-morbidity, and medical history will be recorded.
Clinical monitoring and recording: The study physician will record four hourly vital signs and warning signals in the case report form. Nurses and the study site night physician will record vitals during the night shift trial. Warning indicators will be operationally defined. The project research physician will do a tourniquet test during enrollment. An axillary temperature of 38°C or above indicates fever.
Laboratory investigations: DMCH, MuMCH, and DNCC blood samples will be delivered to icddr,b laboratory for reference value consistency. DMCH, MuMCH, and DNCC admitting physicians will receive the results via WhatsApp group on the same day and receive paper copies for patient files.
Blood samples will be taken from research participants at enrollment, discharge, or deterioration and on day 21 (18-28 days) during recovery. If fever is present on day 5 or 6, 2.5 ml of blood will be drawn for IgM and IgG. Diarrhea patients included will also provide stool samples. The IEDCR and icddr,b labs will be tested. Under-5s can collect 10 ml of blood, while adults can collect 15 ml. Within 6 hours of collection, serum tests should be refrigerated at -70°C. The hospital policy requires sterile plastic tubes to collect l specimens from diarrheal patients at Dhaka Hospital.
A qualitative assessment of experienced healthcare professionals from selected hospitals will examine their real-life experiences with treatment (including symptom management, hospitalization, and recovery), treatment options (including traditional medicines, alternative therapies, and other local remedies), challenges/barriers to treatment, gaps in current treatment approaches, and patient and health care professional preferences. One Research Officer (RO) with an Anthropology degree and qualitative research experience will choose participants and conduct interviews under the supervision of a senior Anthropologist. RO will choose qualitative interviewees based on their dengue treatment experience at the specified hospitals and variety. Eight Key Informant Interviews (KII) will be conducted with dengue treatment professionals from four hospitals. In addition, in-depth interviews (IDIs) will be conducted with eight physicians and eight nurses actively treating at the selected hospitals to understand current treatment practices and best treatment approaches to replicate elsewhere to improve treatment, especially for vulnerable populations. After data saturation, the number of interviews will be calculated.
A verbal autopsy will be performed on every death if the caregiver consents. Then, the study personnel will retrospectively evaluate death instances, collect data, and arrange verbal autopsy from caregivers at DNCC hospital.
Calculating Sample Size: This study's sample size was calculated in two steps to reach a 5% progression of severe dengue. This calculation ensures that the study has the statistical power to identify the effect size and whether clinical and laboratory parameters affect severe Dengue development. First, a minimum sample size of 321 was calculated. Thus, if 321 patients are included, 16 (5% of 321) will have severe Dengue cases, and 305 will be non-severe.
Data analysis: Data management and statistical analyses will use STATA (16.0) and SPSS for Windows. The dataset will be summarized using frequency (%), mean, standard deviation, median, and interquartile range. Statistical plots will be employed to illustrate data distribution and identify outliers. When appropriate, chi-squared or Fisher's Exact tests compare categorical variables, whereas Mann-Whitney tests compare continuous variables.
Multivariable logistic regression will examine the relationship between binary outcomes (e.g., severe Dengue vs. non-severe Dengue) and predictor factors (e.g., age, sex, admission sickness status, laboratory test findings). To measure association strength, odds ratios (OR) and 95% confidence intervals (CI) will be calculated. Statistical significance is evaluated at p-value \< 0.05.
Thematically analyzing verbal autopsy data will reveal dengue-related death trends. Formative study data will be thematically coded to understand treatment approaches and their feasibility. Post-study beginning, a formal Statistical Analysis Plan (SAP) will guide the analysis process, providing openness and rigor.
The expedited committee of the Research Review Committee (RRC) and Ethical Review Committee (ERC) of icddr,b will review the study protocol, data collection tools, and informed consent forms before starting the study. The study will follow the 'Declaration of Helsinki' (2000), ICH, Tripartite Guidelines, and GCP. These protocols protect the rights and integrity of study participants, conduct all study procedures correctly, collect enough data, document it, and verify it.
No patient benefit is expected beyond routine therapy and monitoring. The study only poses a modest risk to participants during blood collection. No additional specimens will be taken for this investigation. Bengali will be used to write and structure the permission form for study subjects without formal education. The patient and study subject's accompanying person will hear the consent form if they cannot read it. The participant can leave the research and decline to answer any questions. This hospital will treat the patient as usual if they refuse the research. Patient data will be kept private, anonymous, and secret. Our study staff will have exclusive access to all medical information, treatment descriptions, and laboratory test results from the specific ward.
Labs accredited for testing:
The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) employs multidisciplinary international and national scientists. It has adequate facilities to treat shock, severe sepsis, and electrolyte abnormalities caused by diarrhea. Dhaka Hospital of icddr,b contains an intensive care section for critically unwell children. A 24-hour backup generator, refrigerator (-20°C), and deep freezer (-80°C) are available. All study-related research can be done at the biochemistry laboratory, which is open 24/7.
Mosquito-borne dengue is a global public health issue in the tropics and subtropics. Dengue is endemic in over 100 countries, according to WHO. Around 40% of the world's population-3.6 billion-lives in dengue-endemic areas. Dengue infects 400 million people, sickens 100 million, and kills 21,000 each year. In studies of acute febrile illness in US visitors returning from South-central and Southeast Asia, South America, Mexico, and the Caribbean, dengue is the main cause due to increased international travel and the popularity of dengue-endemic destinations. Thus, dengue-related US hospitalizations are rising. Prevention methods, such as early detection and prompt clinical therapy, can lower case fatality rates from 10% to \<1%.
National perspective:
Dengue has been hyperendemic in Bangladesh since 2000. The current dengue spike is exceptional in its seasonality and an early fast increase compared to past years, which began in late June. According to WHO, this year's case fatality rate is 0.47%, higher than usual. However, Bangladeshi clinical spectrum, serotype predominance, novel and modified serotypes (DEVN-5), and immunological responses need more research. However, future dengue prevention and treatment techniques require serotype-specific clinical and laboratory indicators and immune reactivity in distinct spectrums.
This research is conducted in hospitals to identify the burden of severe dengue and its link to dengue fever in our country. Dengue fever is now managed supportively without antiviral medication. The cause of severe and potentially deadly dengue is unknown. Prior DENV exposure, co-morbidity, and genetic predisposition may increase the risk of severe dengue sickness. The study results will help us understand and solve the problem. The aim is to assess the clinical and laboratory parameters related to severe Dengue and the transition from non-severe to severe Dengue in hospitalized Bangladeshis.
Primary objectives: To identify factors for progression to severe Dengue in hospitalized patients.
Secondary objectives:
1. To determine the circulating dengue serotype (DENV-1, DENV-2, DENV-3, DNEV-4, and others) about different spectrums of dengue fever in Bangladesh.
2. To determine primary and secondary immune responses (IgG and IgM) following dengue infection \[by examining IgG to IgM ratio (ELISA) with analyzing of DENV NS1 IgG subclass types (ELISA)\] and the association of immune responses to the different spectrum of dengue fever in Bangladesh.
3. To characterize specific laboratory biomarkers (hematocrit level, white blood cell count, platelet count, coagulation profile, serum albumin level, liver enzymes, LDH) and immunological parameters (NS1, IgM, and IgG) associated with severe Dengue cases.
4. Verbal autopsy and retrospective analyses of death cases from the respective hospital.
5. To explore physicians' barriers and challenges in treating Dengue and identify and develop the best treatment approaches through formative research.
Study design: Observational Cohort study Study sites: Four sites/hospitals: Dhaka North City Corporation Hospital (DNCCH), Mugda Medical College and Hospital (MuMCH), Dhaka Medical College Hospital (DMCH), and Dhaka Hospital of icddr,b.
Study population: \>1 year Study period: The study lasts from 1 January 2024 to 31 June 2024. Total enrolment will be for 6 months or until the estimated patient enrolment is fulfilled.
Study Activities:
Screening: The study nurse and health worker will identify eligible patients during hospital admission. After meeting enrolment requirements, the caregiver or attendance will be asked for informed written consent. After consenting, the patient will be enrolled. Patients will give a full history, and the study nurse will record it in CRF. Socio-demographic, household, co-morbidity, and medical history will be recorded.
Clinical monitoring and recording: The study physician will record four hourly vital signs and warning signals in the case report form. Nurses and the study site night physician will record vitals during the night shift trial. Warning indicators will be operationally defined. The project research physician will do a tourniquet test during enrollment. An axillary temperature of 38°C or above indicates fever.
Laboratory investigations: DMCH, MuMCH, and DNCC blood samples will be delivered to icddr,b laboratory for reference value consistency. DMCH, MuMCH, and DNCC admitting physicians will receive the results via WhatsApp group on the same day and receive paper copies for patient files.
Blood samples will be taken from research participants at enrollment, discharge, or deterioration and on day 21 (18-28 days) during recovery. If fever is present on day 5 or 6, 2.5 ml of blood will be drawn for IgM and IgG. Diarrhea patients included will also provide stool samples. The IEDCR and icddr,b labs will be tested. Under-5s can collect 10 ml of blood, while adults can collect 15 ml. Within 6 hours of collection, serum tests should be refrigerated at -70°C. The hospital policy requires sterile plastic tubes to collect l specimens from diarrheal patients at Dhaka Hospital.
A qualitative assessment of experienced healthcare professionals from selected hospitals will examine their real-life experiences with treatment (including symptom management, hospitalization, and recovery), treatment options (including traditional medicines, alternative therapies, and other local remedies), challenges/barriers to treatment, gaps in current treatment approaches, and patient and health care professional preferences. One Research Officer (RO) with an Anthropology degree and qualitative research experience will choose participants and conduct interviews under the supervision of a senior Anthropologist. RO will choose qualitative interviewees based on their dengue treatment experience at the specified hospitals and variety. Eight Key Informant Interviews (KII) will be conducted with dengue treatment professionals from four hospitals. In addition, in-depth interviews (IDIs) will be conducted with eight physicians and eight nurses actively treating at the selected hospitals to understand current treatment practices and best treatment approaches to replicate elsewhere to improve treatment, especially for vulnerable populations. After data saturation, the number of interviews will be calculated.
A verbal autopsy will be performed on every death if the caregiver consents. Then, the study personnel will retrospectively evaluate death instances, collect data, and arrange verbal autopsy from caregivers at DNCC hospital.
Calculating Sample Size: This study's sample size was calculated in two steps to reach a 5% progression of severe dengue. This calculation ensures that the study has the statistical power to identify the effect size and whether clinical and laboratory parameters affect severe Dengue development. First, a minimum sample size of 321 was calculated. Thus, if 321 patients are included, 16 (5% of 321) will have severe Dengue cases, and 305 will be non-severe.
Data analysis: Data management and statistical analyses will use STATA (16.0) and SPSS for Windows. The dataset will be summarized using frequency (%), mean, standard deviation, median, and interquartile range. Statistical plots will be employed to illustrate data distribution and identify outliers. When appropriate, chi-squared or Fisher's Exact tests compare categorical variables, whereas Mann-Whitney tests compare continuous variables.
Multivariable logistic regression will examine the relationship between binary outcomes (e.g., severe Dengue vs. non-severe Dengue) and predictor factors (e.g., age, sex, admission sickness status, laboratory test findings). To measure association strength, odds ratios (OR) and 95% confidence intervals (CI) will be calculated. Statistical significance is evaluated at p-value \< 0.05.
Thematically analyzing verbal autopsy data will reveal dengue-related death trends. Formative study data will be thematically coded to understand treatment approaches and their feasibility. Post-study beginning, a formal Statistical Analysis Plan (SAP) will guide the analysis process, providing openness and rigor.
The expedited committee of the Research Review Committee (RRC) and Ethical Review Committee (ERC) of icddr,b will review the study protocol, data collection tools, and informed consent forms before starting the study. The study will follow the 'Declaration of Helsinki' (2000), ICH, Tripartite Guidelines, and GCP. These protocols protect the rights and integrity of study participants, conduct all study procedures correctly, collect enough data, document it, and verify it.
No patient benefit is expected beyond routine therapy and monitoring. The study only poses a modest risk to participants during blood collection. No additional specimens will be taken for this investigation. Bengali will be used to write and structure the permission form for study subjects without formal education. The patient and study subject's accompanying person will hear the consent form if they cannot read it. The participant can leave the research and decline to answer any questions. This hospital will treat the patient as usual if they refuse the research. Patient data will be kept private, anonymous, and secret. Our study staff will have exclusive access to all medical information, treatment descriptions, and laboratory test results from the specific ward.
Labs accredited for testing:
The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) employs multidisciplinary international and national scientists. It has adequate facilities to treat shock, severe sepsis, and electrolyte abnormalities caused by diarrhea. Dhaka Hospital of icddr,b contains an intensive care section for critically unwell children. A 24-hour backup generator, refrigerator (-20°C), and deep freezer (-80°C) are available. All study-related research can be done at the biochemistry laboratory, which is open 24/7.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dengue Fever With Warning Signs
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dengue fever with warning signs with Ns1 positive and or IgM positive
* Informed written consent or assent.
* Informed written consent or assent.
Exclusion Criteria
* Severe dengue during screening or denied consenting
Minimum Eligible Age
1 Year
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lubaba Shahrin, MBBS, FCPS
Role: PRINCIPAL_INVESTIGATOR
Scientist, ICDDRB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
International Centre for Diarrheal Disease Research Bangladesh
Dhaka, , Bangladesh
Site Status
International Centre for Diarrheal Disease Research Bangladesh
Dhaka, , Bangladesh
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Bangladesh
References
Explore related publications, articles, or registry entries linked to this study.
Wang SM, Sekaran SD. Early diagnosis of Dengue infection using a commercial Dengue Duo rapid test kit for the detection of NS1, IGM, and IGG. Am J Trop Med Hyg. 2010 Sep;83(3):690-5. doi: 10.4269/ajtmh.2010.10-0117.
Reference Type
BACKGROUND
Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013 Jul;158(7):1445-59. doi: 10.1007/s00705-013-1645-3. Epub 2013 Mar 8.
Reference Type
BACKGROUND
Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. Med J Armed Forces India. 2015 Jan;71(1):67-70. doi: 10.1016/j.mjafi.2014.09.011. Epub 2014 Nov 24.
Reference Type
BACKGROUND
Changal KH, Raina AH, Raina A, Raina M, Bashir R, Latief M, Mir T, Changal QH. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: an observational hospital based clinico-serological study from North India. BMC Infect Dis. 2016 Nov 28;16(1):715. doi: 10.1186/s12879-016-2053-6.
Reference Type
BACKGROUND
Vicente CR, Herbinger KH, Froschl G, Malta Romano C, de Souza Areias Cabidelle A, Cerutti Junior C. Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitoria, Brazil. BMC Infect Dis. 2016 Jul 8;16:320. doi: 10.1186/s12879-016-1668-y.
Reference Type
BACKGROUND
Delli Ponti R, Mutwil M. Structural landscape of the complete genomes of dengue virus serotypes and other viral hemorrhagic fevers. BMC Genomics. 2021 May 17;22(1):352. doi: 10.1186/s12864-021-07638-7.
Reference Type
BACKGROUND
Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K. Clinical predictors of severe dengue: a systematic review and meta-analysis. Infect Dis Poverty. 2021 Oct 9;10(1):123. doi: 10.1186/s40249-021-00908-2.
Reference Type
BACKGROUND
Ng WY, Atan R, Mohd Yunos N, Bin Md Kamal AH, Roslan MH, Quah KY, Teh KX, Zaid M, Kassim M, Mariapun J, Ngim CF, Dhanoa A, Yeo TW. A double whammy: The association between comorbidities and severe dengue among adult patients-A matched case-control study. PLoS One. 2022 Sep 20;17(9):e0273071. doi: 10.1371/journal.pone.0273071. eCollection 2022.
Reference Type
BACKGROUND
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Anonymous dataset upor request by scientific use. Data will be shared by the Institutional Review Board.
https://www.icddrb.org
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
https://www.icddrb.org
International Centre for Diarrheal Disease Research Bangladesh
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-23077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649
UNKNOWN
Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock
NCT02060773
UNKNOWN
Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients
NCT05143736
RECRUITING
Sepsis Characterization in Kilimanjaro
NCT05139459
COMPLETED
Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis
NCT03655899
TERMINATED
Early-Onset Sepsis an NICHD/CDC Surveillance Study
NCT02410486
COMPLETED
Pro-thrombotic Status in Patients with SARS-Cov-2 Infection
NCT04343053
COMPLETED
NA
Mitochondrial Function in Septic Patients
NCT03748537
COMPLETED
NA
Initiation of Hydrocortisone for the Treatment of Septic Shock
NCT02580240
COMPLETED
NA
Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)
NCT02567305
UNKNOWN
Sepsis: From Syndrome to Personalized Care
NCT04203979
RECRUITING
A Prospective Observational Study of Sepsis
NCT05309889
UNKNOWN
Effect of Metformin Use on Mortality in Diabetic and Non Diabetic Patients With Sepsis and Septic Shock.
NCT05572060
UNKNOWN
NA
Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand
NCT02217592
COMPLETED
Establishment of Early Diagnosis and Monitoring Model for Sepsis Patients
NCT04974411
UNKNOWN
Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
NCT06904001
ENROLLING_BY_INVITATION
An Observational Study to Learn About the Occurrence of Disseminated Intravascular Coagulation Among Adults With Sepsis in Japan
NCT06373159
COMPLETED
Monitoring of Perfusion in Sepsis and Malaria
NCT03641534
COMPLETED
Effect of Montelukast Versus Co Enzyme in Sepsis
NCT05293132
COMPLETED
PHASE2/PHASE3
Gender-based Differences in the Outcome of the Treatment of Persistent Septic Shock With Hydrocortisone
NCT06537180
COMPLETED
German Lactat Clearance in Severe Sepsis
NCT01929772
COMPLETED
Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy
NCT00410111
COMPLETED
The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock
NCT05402553
UNKNOWN
PHASE1/PHASE2
Hospital Orientation Since SAMU Regulation Centre Call
NCT03237403
UNKNOWN
Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis
NCT06657781
RECRUITING